Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 May;10(5):534-41.
doi: 10.1016/j.jpain.2008.12.003. Epub 2009 Feb 23.

Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat

Elizabeth K Joseph  1 , Jon D Levine
Affiliations
Comparative Study

Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat

Elizabeth K Joseph et al. J Pain. 2009 May.

Abstract

Although platinum-based cancer chemotherapies produce painful peripheral neuropathy as dose-limiting side effects, there are important differences in the pain syndromes produced by members of this class of drugs. In the rat, cisplatin-induced hyperalgesia has latency to onset of 24 to 48 hours, is maximal by 72 to 96 hours, and is attenuated by inhibitors of caspase signaling but not by inhibitors of the mitochondrial electron transport chain (mETC) and antioxidants. In contrast, oxaliplatin-induced mechanical hyperalgesia is already present by 5 minutes and peaks by 20 minutes. Whereas oxaliplatin hyperalgesia persists for weeks, starting around day 10 to 15, its severity decreases to a lower 2nd plateau level. The rapid-onset 1st plateau in oxaliplatin-induced hyperalgesia was characterized by prominent cold allodynia and in contrast to cisplatin was attenuated by inhibitors of the mETC and antioxidants but not inhibitors of caspase signaling. However, tested later during the 2nd plateau, it was characterized by less intense hyperalgesia and no cold allodynia and was attenuated by inhibitors of caspase signaling as well as by inhibitors of the mETC and by antioxidants.

Perspective: The findings of this study distinguish between the neuropathic pain syndromes produced by members of a single chemical class of anticancer drugs and suggest that the underlying mechanisms of various forms of peripheral neuropathy may be different. Further, it defines the need for selective therapy for different types of neuropathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Time course of Oxaliplatin (0.5 mg/kg, i.v. reported from to show the two plateau of Oxaliplatin hyperalgesia, and 2 mg/kg, i.v., n =12/group) and Cisplatin (2 mg/kg/i.v. n = 6/group) induced mechanical hyperalgesia. Oxaliplatin (2 mg/kg, i.v.) induced hyperalgesia lasted over 6 weeks and on the 42nd day there still was significant (p<0.01) hyperalgesia, while Cisplatin hyperalgesia lasted less than 2 weeks. Also there was a significant difference in the intensity of Oxaliplatin (2 mg/kg, i.v.) hyperalgesia between day 5 and day 20 (p<0.01). B. Onset of mechanical hyperalgesia induced by Oxaliplatin and Cisplatin (both 2 mg/kg/i.v. n = 6/group). Oxaliplatin induced hyperalgesia has markedly faster onset than Cisplatin hyperalgesia.
Figure 2
Figure 2
A. Mechanical allodynia induced by Oxaliplatin (1st and 2nd plateau) and Cisplatin (n = 6/group). B. Effect of Oxaliplatin (1st and 2nd plateau) and Cisplatin (n = 6/group) on response to noxious heat, measured by Hargreaves test, and C. Effect of Oxaliplatin (1st and 2nd plateau) and Cisplatin (n = 6/group), on response to noxious cold (10°C). The level of significance is denoted by (*) where p<0.05 = *, p<0.01 = ** and p<0.001 = ***. OXP = Oxaliplatin, CISP = Cisplatin.
Figure 3
Figure 3
Effect of mitochondrial electron transport complex (mETC) inhibitors rotenone, 3-NP, antimycin, sodium cyanide and oligomycin, antioxidants acetyl-L-carnitine (ALC), a-lipoic acid (a-lipo) and vitamin C, and a caspase inhibitor (ZVAD-FMK) on the A. acute, and B. chronic effect of Oxaliplatin-induced mechanical hyperalgesia, and C. on Cisplatin-induced mechanical hyperalgesia (n=6/group). All inhibitors were administered to different groups of Oxaliplatin and Cisplatin treated rats.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abrey LE, Correa DD. Treatment-related neurotoxicity. Hematol Oncol Clin North Am. 2005;19:729–738. viii. - PubMed
    1. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406:25–32. - PubMed
    1. Aley KO, Levine JD. Role of protein kinase A in the maintenance of inflammatory pain. J Neurosci. 1999;19:2181–2186. - PMC - PubMed
    1. Aley KO, Levine JD. Different peripheral mechanisms mediate enhanced nociception in metabolic/toxic and traumatic painful peripheral neuropathies in the rat. Neuroscience. 2002;111:389–397. - PubMed
    1. Aley KO, Martin A, McMahon T, Mok J, Levine JD, Messing RO. Nociceptor sensitization by extracellular signal-regulated kinases. J Neurosci. 2001;21:6933–6939. - PMC - PubMed

Publication types

MeSH terms